Prestige Biologics
Key metrics
Earnings
| Revenue, Q3 2026 | ₩2.3bn |
|---|---|
| Revenue QoQ | Not available |
| Revenue YoY | -34.8% |
| Operating income, Q3 2026 | -₩16.3bn |
| Operating income QoQ | Not available |
| Operating income YoY | -124.5% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 5,516,340 shares |
| Potential new shares, % of shares | 7.1% |
| Conversion price adjustments, last 12 months | 2 |
Supply contracts
| Supply contracts, last 12 months | ₩39.2bn |
|---|---|
| Supply contracts vs prior-year revenue | 312.7% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 15 |
|---|---|
| DART filings, previous 3 months | 9 |
Insider transactions
| Open-market buys, last 12 months (shares) | 186,100 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩289m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 186,100 shares |
| Insiders who bought, last 12 months | 2 |
Insider transactions (last 12 months)
Open-market buys: 186,100 shares (₩289m). Open-market sells: 0 shares (₩0). Net open-market buying: +186,100 shares. Insiders who bought: 2.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | Lim Yeong-su (Registered director) | Open-market buy | +11,500 shares | ₩1,161 | ₩13m | |
| Nov 6, 2026 | Lim Yeong-su (Registered director) | Open-market buy | +3,000 shares | ₩1,168 | ₩4m | |
| Nov 5, 2026 | Lim Yeong-su (Registered director) | Open-market buy | +39,000 shares | ₩1,150 | ₩45m | |
| Nov 5, 2026 | Lim Yeong-su (Registered director) | Other (OTC buy) | +55,000 shares | ₩1,179 | ₩65m | |
| Nov 4, 2026 | Lim Yeong-su (Registered director) | Open-market buy | +29,000 shares | ₩1,131 | ₩33m | |
| Jul 9, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +3,600 shares | ₩1,985 | ₩7m | |
| Jun 30, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +8,000 shares | ₩1,946 | ₩16m | |
| Jun 29, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +16,213 shares | ₩1,942 | ₩31m | |
| Jun 26, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +28,787 shares | ₩1,866 | ₩54m | |
| Jun 25, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +22,000 shares | ₩1,868 | ₩41m | |
| Jun 24, 2026 | Kim Jin-u (Registered director, 10%+ shareholder) | Open-market buy | +25,000 shares | ₩1,814 | ₩45m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩12.5bn | -₩33.7bn |
| 2024 | ₩2.2bn | -₩33.4bn |
| 2023 | ₩1.7bn | -₩22.1bn |
Filing timeline
-
Prestige Biologics signs ₩15.5bn commercial API manufacturing supply contract
Prestige Biologics Co., Ltd. filed a supply contract dated Nov 12, 2026 for commercial active pharmaceutical ingredient contract manufacturing, with a contract amount of ₩15.5bn. The filing reports the contract as 58.1% of revenue. The contract period runs from Nov 12, 2026 to Dec 31, 2027.